Marshall Urist - 20 May 2021 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role
EVP & Co-Head Research & Inv.
Signature
/s/ Jason Mehar, as Attorney-in-Fact for Marshall Urist
Issuer symbol
RPRX
Transactions as of
20 May 2021
Transactions value $
-$82,159
Form type
4
Filing time
24 May 2021, 20:10:50 UTC
Previous filing
11 May 2021
Next filing
04 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPRX Class A Ordinary Shares Sale -$78,059 -1,900 -3.82% $41.08 47,800 20 May 2021 Direct F1
transaction RPRX Class A Ordinary Shares Sale -$4,100 -100 -0.21% $41 47,700 21 May 2021 Direct
holding RPRX Class A Ordinary Shares 19,020 20 May 2021 By IRA
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.20 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

All reported transactions were effected pursuant to 10b5-1 plans adopted by the reporting person on March 29, 2021.